Chen D, Misra A, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients J Clin Endocrinol Metab. 2002 Nov;87(11):4845-56.

Holstein A, Plaschke A, Egberts EH. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection Exp Clin Endocrinol Diabetes. 2001;109(8):389-92.

Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus Am J Med. 2005 Apr;118 Suppl 2:23S-28S.

Referenca 1

Referenca 2

Aldersberg, D. & Mayer, M. Results of prolonged medical treatment of obesity. Journal of Clinical Endocrinology, 9, 1949, 275–284.

Rotter, J.B. Generalized expectancies of internal versus external control of reinforcements. Psychological Monographs, 80, 1966.

Fitzgibbon, Marian L.; Stolley, Melinda R. & Kirschenbaum, Daniel S. Health Psychology, Vol 12(5), September 1993, 342–345.

Chang CC, Cheng CJ, Sung CC, Chiueh TS, Lee CH, Chau T & Lin SH. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinology, 2013; 169: 529–536.

Kung AW. Clinical review: thyrotoxic periodic paralysis: a diagnostic challenge. Journal of Clinical Endocrinology and Metabolism. 2006; 91:2490–2495.

Falhammar H, Thore´n M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. Endocrine, 2013; 43: 274–284.